UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices)
(512 ) 215-2630
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Section 2 - Financial Information
Item 2.02. Results of Operations and Financial Condition.
On May 3, 2023, Lumos Pharma, Inc., a Delaware corporation (the “Company”), issued a press release providing an operational update and reporting results for the first quarter ended March 31, 2023 ("Press Release").
A copy of the Press Release and the First Quarter 2023 Financial Results Presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.
The information in this Current Report, including Exhibits 99.1 and 99.2 attached hereto are furnished under Item 2.02 of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |||||||
| 99.1 | Press Release, dated May 3, 2023, entitled "Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates" | |||||||
| 99.2 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 3, 2023
| LUMOS PHARMA, INC., a Delaware corporation | |||||
| By: | /s/ Richard J. Hawkins | ||||
| Richard J. Hawkins | |||||
| Its: | Chief Executive Officer | ||||
Exhibit 99.1
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials --
-- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 --
-- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 –
-- Conference Call Scheduled for Today at 4:30pm ET --
AUSTIN, TX, May 3, 2023 – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the quarter ended March 31, 2023.
“With both our Phase 2 OraGrowtH210 and OraGrowtH212 Trials evaluating oral LUM-201 in moderate (idiopathic) PGHD fully enrolled, we look forward to announcing top line results in the fourth quarter of 2023,” said Rick Hawkins, Chair and CEO of Lumos Pharma. “We were also pleased to see updated interim data from these two OraGrowtH Trials highlighted at the 2023 IMPE meeting and accepted for presentation at the upcoming 2023 PES annual meeting. These data reinforce our prediction from our interim analysis that the 1.6 mg/kg dose is on track to meet growth expectations in moderate PGHD patients based on historical database averages. The presented data further demonstrate that LUM-201 possesses both a favorable safety profile and a natural, endogenous mechanism of action with potency to stimulate meaningful growth in this idiopathic PGHD patient population.”
Recent Highlights
•Interim Data from OraGrowtH210 and OraGrowtH212 Trials accepted for presentation at annual Pediatric Endocrine Society (PES) Meeting (May 5-8)
•An oral presentation on OraGrowtH210 Trial interim data will be given by Andrew Dauber, MD, Chief of Endocrinology, Children’s National Hospital
•A poster presentation on OraGrowtH212 Trial interim data by Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, will be presented by David B. Karpf, MD, Chief Medical Officer, Lumos Pharma
•Additional OraGrowtH212 Trial data and interim OraGrowtH210 Trial data were presented at the 2023 International Meeting of Pediatric Endocrinology (IMPE) (Mar 4-7)
•An oral presentation by Fernando Cassorla, MD, on OraGrowtH212 data further supported the pulsatile MOA of LUM-201 and highlighted growth stimulated by oral LUM-201 in PEM-positive PGHD subjects
•OraGrowtH210 interim data were presented in a poster by Alison Lunsford, MD, Assistant Professor, Texas Tech Physicians of Amarillo, demonstrating the favorable safety and tolerability profile of LUM-201 and that the 1.6 mg/kg/day LUM-201 dose demonstrated 8.6 cm/yr 6-month annualized height velocity in line with historical growth for moderate idiopathic PGHD patients treated with injectable standard of care (rhGH)
•OraGrowtH210 and OraGrowtH212 Trials are fully enrolled as announced on February 28, 2023
•Between interim and full enrollment, age and other baseline characteristics for OraGrowtH210 subjects converged across 1.6mg LUM-201 and rhGH cohorts as predicted given the stratification of the trial by age and the balancing effect of the additional subjects included at full enrollment
•Primary outcome data from OraGrowtH210 and OraGrowtH212 Trials are expected Q4 2023
Exhibit 99.1
Financial Results for the Quarter Ended March 31, 2023
Cash Position – Lumos Pharma ended the quarter on March 31, 2023 with cash, cash equivalents and short-term investments totaling $58.0 million compared to $67.4 million on December 31, 2022. The Company expects an average cash use of approximately $9.5 to $10.5 million per quarter through 2023. Cash on hand as of March 31, 2023 is expected to support operations into the third quarter of 2024, well beyond top line results from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials expected in the fourth quarter of 2023.
R&D Expenses – Research and development expenses for the quarter ended March 31, 2023 were $4.4 million, an increase of approximately $0.1 million compared to the same period in 2022.
G&A Expenses – General and administrative expenses for the quarter ended March 31, 2023 were $4.4 million, an increase of approximately $0.7 million over the same period in 2022, primarily due to increases of $0.4 million in licensing expenses, $0.1 million in personnel-related expenses and $0.2 million in travel expenses.
Net Loss – The net loss for the quarter ended March 31, 2023 was $7.3 million compared to a net loss of $7.7 million for the same period in 2022.
Lumos Pharma had 8,183,296 shares outstanding as of March 31, 2023.
Conference Call and Webcast Details
The Company has scheduled a conference call and webcast for 4:30 p.m. ET today to discuss its financial results and to give an update on clinical programs. There will also be a question-and-answer session following management’s prepared remarks.
Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast may be accessed through this Webcast Link and may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available after the date of the call and may be accessed through the same link above or found on our website.
About Lumos Pharma’s Clinical Trials
Phase 2 OraGrowtH210 Trial of Oral LUM-201 in PGHD
The OraGrowtH210 Trial is a multi-site, global trial evaluating orally administered LUM-201 at three dose levels (0.8, 1.6, 3.2 mg/kg/day) against a standard 0.34 mcg/kg/day dose of injectable rhGH in 82 subjects diagnosed with idiopathic (moderate) PGHD, all of whom are also Predictive Enrichment Marker (PEM) positive. The objective of this trial is to identify the optimal dose of LUM-201 to be used in a Phase 3 registration trial, based on annualized height velocity from a 6-month dataset with durability data of up to 24 months, and to prospectively confirm the utility of our PEM strategy. The complete set of 6-month, primary outcome data for up to 82 subjects is anticipated in the fourth quarter of 2023.
OraGrowtH212 Trial Evaluating PK/PD and Pulsatility of Oral LUM-201 in PGHD
The OraGrowtH212 Trial is a single site, open-label trial evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) effects of oral LUM-201 in 22 PGHD subjects at two dose levels, 1.6 and 3.2 mg/kg/day. The primary objective of the OraGrowtH212 Trial is to confirm prior clinical data demonstrating that the restoration of natural pulsatile release of endogenous growth hormone from LUM-201 therapy, contributes to its efficacy in PGHD. The primary endpoint for this trial is 6 months of PK/PD (pulsatility) and height velocity data in the
Exhibit 99.1
randomized subjects. Subjects will be allowed to remain on treatment until they reach a bone age of 14 for females and 16 for males reflecting near-adult height. Primary data readout is anticipated in the fourth quarter of 2023.
Switch Study, OraGrowtH213 Trial, Evaluating LUM-201 in OraGrowtH210 Subjects Previously on rhGH
The OraGrowtH213 Trial is an open-label, multi-center, Phase 2 study evaluating the growth effects and safety of LUM-201 following 12 months of daily rhGH in up to 20 idiopathic PGHD patients who have completed the OraGrowtH210 Trial. Subjects will be administered LUM-201 at a dose level of 3.2 mg/kg/day for up to 12 months.
Lumos Pharma Collaboration with Massachusetts General Hospital Evaluating LUM-201 in NAFLD
Lumos Pharma has entered a collaboration with Massachusetts General Hospital (MGH) to evaluate LUM-201 in patients with nonalcoholic fatty liver disease (NAFLD). GH is a critical stimulator of lipolysis, and shows anti-inflammatory effects, and preclinical data suggest that amplifying GH secretion has the potential to reduce hepatic steatosis and prevent NAFLD progression. Interestingly, enhancing the natural pulsatile release of GH has been shown clinically in short-term studies to be more efficacious in inducing lipolysis than continuous infusions of GH. This MGH investigator-initiated trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD. The trial will evaluate a dose of 25 mg/day of LUM-201 in 10 subjects with NAFLD and relative IGF-1 deficiency. The primary endpoints will be to determine the reduction in liver lipid content and inflammation, and impact on fibrosis in these subjects administered oral LUM-201 compared to each subject’s baseline.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in several Phase 2 clinical trials for the treatment of Pediatric Growth Hormone Deficiency (PGHD): the dose-finding OraGrowtH210 Trial; a PK/PD mechanistic trial, the OraGrowtH212 Trial; and a switch trial, the OraGrowtH213 Trial. If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part, gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.
We are passionate about our business - including LUM-201 and the potential it may have to help patients in the clinic. This passion feeds our optimism that our efforts will be successful and bring about therapeutics that are safe, efficacious, and offer a meaningful change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.
We have attempted to identify forward-looking statements by using words such as “projected,” "upcoming," "will," “would,” "plan," “intend,” "anticipate," "approximate," "expect," “potential,” “imminent,” and similar references to future periods or the negative of these terms. Not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding the encouraging growth response in our LUM-201 trials, progress in our clinical efforts including the timing of expected results on our trials and our ability to continue advancing our trials, 1.6 mg/kg/day as the optimal dose for our Pivotal Phase 3 trial, plans related to initiation and execution of clinical trials; our prediction from our interim analysis that the
Exhibit 99.1
1.6 mg/kg dose is on track to meet growth expectations in moderate PGHD patients based on historical database averages, that the presented data further demonstrate that LUM-201 possesses both a favorable safety profile and a natural, endogenous mechanism of action with potency to stimulate meaningful growth in this idiopathic PGHD patient population, plans related to moving additional indications into clinical development; future financial performance, results of operations, our expected average cash use per quarter through 2023 and that cash on hand as of March 31, 2023 is expected to support operations into the third quarter of 2024 and any other statements other than statements of historical fact.
We wish we were able to predict the future with 100% accuracy, but that just is not possible. Our forward-looking statements are neither historical facts nor assurances of future performance. You should not rely on any of these forward-looking statements and, to help you make your own risk determinations, we have provided an extensive discussion of risks that could cause actual results to differ materially from our forward-looking statements including risks related to the final results of our LUM-201 Trials being different than our interim results, the effects of pandemics, other widespread health problems or military conflicts including the Ukraine-Russia conflict, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain and maintain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements including information in the "Risk Factors" section and elsewhere in Lumos Pharma’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other reports filed with the SEC. All of these documents are available on our website. Before making any decisions concerning our stock, you should read and understand those documents.
We anticipate that subsequent events and developments will cause our views to change. We may choose to update these forward-looking statements at some point in the future, however, we disclaim any obligation to do so. As a result, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
###
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Exhibit 99.1
| Lumos Pharma, Inc. | ||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||
| (unaudited) | ||||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||||
| Three Months Ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||
| Royalty revenue | $ | 691 | $ | 111 | ||||||||||
| Total revenues | 691 | 111 | ||||||||||||
| Operating expenses: | ||||||||||||||
| Research and development | 4,369 | 4,221 | ||||||||||||
| General and administrative | 4,357 | 3,621 | ||||||||||||
| Total operating expenses | 8,726 | 7,842 | ||||||||||||
| Loss from operations | (8,035) | (7,731) | ||||||||||||
| Other income and expense: | ||||||||||||||
| Other income, net | 119 | 6 | ||||||||||||
| Interest income | 570 | 5 | ||||||||||||
| Other income, net | 689 | 11 | ||||||||||||
| Net loss | $ | (7,346) | $ | (7,720) | ||||||||||
| Net loss per share: | ||||||||||||||
| Basic and diluted | $ | (0.89) | $ | (0.92) | ||||||||||
| Weighted average number of common shares outstanding: | ||||||||||||||
| Basic and diluted | 8,239,941 | 8,357,969 | ||||||||||||
| Other comprehensive income: | ||||||||||||||
| Unrealized gain on short-term investments | 4 | — | ||||||||||||
| Total comprehensive loss | $ | (7,342) | $ | (7,720) | ||||||||||
Exhibit 99.1
| Lumos Pharma, Inc. | |||||||||||
| Condensed Consolidated Balance Sheets | |||||||||||
(In thousands, except share and per share amounts) | |||||||||||
| March 31, | December 31, | ||||||||||
| 2023 | 2022 | ||||||||||
| (unaudited) | |||||||||||
| Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 44,038 | $ | 56,007 | |||||||
| Short-term investments | 13,945 | 11,352 | |||||||||
Prepaid expenses and other current assets | 5,070 | 4,427 | |||||||||
Income tax receivable | 200 | 223 | |||||||||
Total current assets | 63,253 | 72,009 | |||||||||
| Non-current assets: | |||||||||||
Property and equipment, net | 52 | 53 | |||||||||
Right-of-use asset | 420 | 230 | |||||||||
Total non-current assets | 472 | 283 | |||||||||
| Total assets | $ | 63,725 | $ | 72,292 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current liabilities: | |||||||||||
Accounts payable | $ | 837 | $ | 275 | |||||||
| Accrued expenses | 3,948 | 6,200 | |||||||||
| Current portion of lease liability | 232 | 233 | |||||||||
| Total current liabilities | 5,017 | 6,708 | |||||||||
| Long-term liabilities: | |||||||||||
| Royalty obligation payable to Iowa Economic Development Authority | 6,000 | 6,000 | |||||||||
| Lease liability | 189 | — | |||||||||
| Total long-term liabilities | 6,189 | 6,000 | |||||||||
| Total liabilities | $ | 11,206 | $ | 12,708 | |||||||
| Commitments and contingencies: | |||||||||||
| Stockholders' equity: | |||||||||||
Undesignated preferred stock, $0.01 par value: Authorized shares - 5,000,000 at March 31, 2023 and December 31, 2022; issued and outstanding shares - 0 at March 31, 2023 and December 31, 2022 | — | — | |||||||||
Common stock, $0.01 par value: Authorized shares - 75,000,000 at March 31, 2023 and December 31, 2022; issued 8,200,043 and 8,283,708 at March 31, 2023 and December 31, 2022, respectively and outstanding shares - 8,183,296 and 8,267,968 at March 31, 2023 and December 31, 2022, respectively | 81 | 82 | |||||||||
Treasury stock, at cost, 16,747 and 15,740 shares at March 31, 2023 and December 31, 2022, respectively | (174) | (170) | |||||||||
| Additional paid-in capital | 187,446 | 187,164 | |||||||||
| Accumulated deficit | (134,829) | (127,483) | |||||||||
| Accumulated other comprehensive loss | (5) | (9) | |||||||||
| Total stockholders' equity | $ | 52,519 | $ | 59,584 | |||||||
| Total liabilities and stockholders' equity | $ | 63,725 | $ | 72,292 | |||||||
1 First Quarter 2023 Financial Results & Clinical Update May 3, 2023
2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made solely for informational purposes, and no representation or warranty, express or implied, is made by Lumos or any of its representatives as to the information contained in these materials or disclosed during any related presentations or discussions. This presentation contains forward-looking statements of Lumos that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We are passionate about our business, including LUM-201 and the potential it may have to help patients in the clinic. This passion feeds our optimism that our efforts will be successful and bring about therapeutics that are safe, efficacious, and offer a meaningful change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. We have attempted to identify forward-looking statements by using words such as “projected,” "upcoming," "will," “would,” "plan," “intend,” "anticipate," "approximate," "expect," “potential,” “imminent,” and similar references to future periods or the negative of these terms. Not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding progress in our clinical efforts including comments concerning screening and enrollment for our trials, momentum building in our LUM-201 program for PGHD, anticipated timing of interim analyses of trials, LUM-201’s therapeutic potential when administered to pediatric subjects with idiopathic or moderate growth hormone deficiency, that the interim sample size should be adequate to provide an initial indication of LUM 201’s impact, expecting the primary outcome data readout for our trials, market size potential for LUM-201, predictions regarding LUM-201, goals with respect to LUM-201, the potential to expand our LUM-201 platform into other indications, future financial performance, results of operations, cash position, cash use rate and sufficiency of our cash resources to fund our operating requirements through the primary outcome data readout from the OraGrowtH210 and OraGrowtH212 Trials, and any other statements other than statements of historical fact. We wish we were able to predict the future with 100% accuracy, but that just is not possible. Our forward-looking statements are neither historical facts nor assurances of future performance. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make due to a number of important factors, including potential material differences between the interim results of our LUM-201 trials and the final results of the trials which are not known at this time, the effects of pandemics (including COVID-19), other widespread health problems, the Ukraine-Russia conflict, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements. You should not rely on any of these forward-looking statements and, to help you make your own risk determinations, we have provided an extensive discussion of risks that could cause actual results to differ materially from our forward-looking statements in the "Risk Factors" section and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022, as well as other reports filed with the SEC including our Quarterly Reports on Form 10-Q filed after such Annual Report. All of these documents are available on our website. Before making any decisions concerning our stock, you should read and understand those documents. We anticipate that subsequent events and developments will cause our views to change. We may choose to update these forward-looking statements at some point in the future; however, we disclaim any obligation to do so. As a result, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. The data contained herein is derived from various internal and external sources. All of the market data in the presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Further, no representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. 5.3.2023
3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Officer • Lori Lawley, Chief Financial Officer
4 OraGrowtH210 Trial Baseline Characteristics at 50% & 100% Enrollment LUM-201 1.6 mg Mean (SD) N=10 rhGH Mean (SD) N=10 LUM-201 1.6 mg Mean (SD) N=22 rhGH Mean (SD) N=20 Age (months) 99.3 (28.3) 90.3 (26.7) 95.2 (27.3) 91.4 (23.3) Height (cm) 114.6 (9.6) 111.6 (11.9) 113.0 (11.0) 112.3 (10.5) Height SDS -2.35 (0.62) -2.29 (0.43) -2.42 (0.68) -2.23 (0.41) IGF-1 SDS -1.17 (0.72) -1.37 (0.48) -1.40 (0.57) -1.39 (0.47) MPH (cm) 166.98 (7.15) 168.78 (8.85) 165.4 (7.4) 169.1 (8.26) MPH SDS∆ 1.76 (0.60) 1.76 (0.73) 1.69 (0.81) 1.91 (0.65) BA Delay (yrs) 1.9 (0.5) 1.8 (1.0) 1.8 (0.9) 1.9 (0.9) BMI SDS1 -0.35 (0.79) +0.31 (1.05) -0.27 (0.90) +0.01 (0.95) * Preliminary assessment 1 Yang, et al. Nature Sci Rep 2019, 9(1); 16181 SDS = Standard deviation score MPH = Mid-parental height (Child’s target height) MPH SDS delta = SD’s from target height BA = Bone age BMI = Body mass index At 50% enrollment At 100% enrollment* Imbalance between LUM-201 & rhGH arms narrows at full enrollment, which we expect will diminish the rhGH outlier impact
5 Additional Highlights: International Meeting of Pediatric Endocrinologists (IMPE) Oral Presentation: • Dose-dependent Increase in GH AUC0-12h with LUM-201 in Idiopathic Pediatric GH Deficiency (iPGHD) from the Interim Analysis Data of the OraGrowtH212 Trial, Cassorla, F. Poster Presentation: • Baseline Demographics of the OraGrowtH210 Trial Studying LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD) Interim Analysis Data, Lunsford, A. pre-treat LUM-201 6 mo 0 2 4 6 8 10 12 A n n u a li z e d H e ig h t V e lo c it y (c m /y r) 3.2 mg/kg (n=7) 1.6 mg/kg (n=8) LUM-201 raised Annualized Height Velocity from baseline after 6 months on therapy N 10 N 3075 N 433 N 100 8.3 cm/yr 8.6 8.3 8.3 8.6 0 4 8 12 rhGH rhGH rhGH GeN.1 iPGHD2 KIGS3 LUM-201 1.6 mg/kg Sources: 1 Blum et al JES 2021, 2 Lechuga-Sancho et al JPEM 2009, 3 Ranke et al JCEM 2010 LUM-201 1.6 mg/kg/day cohort grew 8.6 cm/year, in line with the expected rate of ~ 8.3 cm/year for moderate idiopathic PGHD patients from multiple historical datasets OraGrowtH210 Historical rhGH AHV data Expected AHV for Moderate PGHD OraGrowtH212 Trial
6 Additional Highlights • Oral Presentation: Growth Response to LUM-201 in the OraGrowtH210 Trial in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Interim Analysis Data (41 Subjects), Dauber, A. • Poster Presentation: Observed IGF-1 Serum Concentration Increase Within Normal Range After Prolonged Daily Oral LUM-201 Administration in Idiopathic Pediatric Growth Hormone Deficiency from the OraGrowtH212 Trial: Interim Analysis Data, Cassorla, F. • LUM-201 in NAFLD – pilot trial continues to enroll • If granted, novel formulation patent would offer LUM-201 protection into Q4 2042, beyond current IP protection to 2036 and additional Orphan Drug Designation protection from time of drug approval Pediatric Endocrine Society (PES) 2023 Presentations Massachusetts General initiated NAFLD pilot trial ongoing LUM-201 novel formulation patent filed • Narrowed next indication targets for LUM-201 to ISS and PWS with analysis continuing Next target indications narrowed for LUM-201 ISS Idiopathic Short Stature PWS Prader-Willi Syndrome
7 Lumos Pharma Financial Information as of March 31, 2023 Values in USD Cash, equivalents & short-term investments $58.0M Debt $0 Shares Outstanding 8.2M Cash Use per Quarter in 2023 $9.5-$10.5M Fiscal Year End December 31 LUMO Cash, cash equivalents, and short-term investments to support operations into 3Q 2024, beyond primary outcome data readouts for OraGrowtH210 and OraGrowtH212 Trials 4Q 2023
8 Investment Highlights Lead asset targeting children with growth disorders PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for growth hormone deficiency (GHD) disorders • LUM-201 acts within natural endocrine pathway, differentiated from injectable therapies • Potential to disrupt significant subset of sizable injectable market for GHD • Worldwide injectable market for GHD disorders is $3.4 billion* • Market for initial oral LUM-201 indication, Pediatric GHD (PGHD), is $1.2 billion* • Prior data support potential efficacy of LUM-201 in multiple GHD disorders • Cash balance of $58.0 million as of close of 1Q 2023 • Cash runway into 3Q 2024, beyond OraGrowtH210 & OraGrowtH212 primary outcome data Late-stage Trials in PGHD • Enrollment completed for Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials • Primary outcome data expected 4Q 2023 • Interim data showed LUM-201 met growth expectations • Enriched patient population de-risks clinical program as all subjects randomized demonstrate a response to LUM-201 in stimulation test